Terence Flynn
Stock Analyst at Morgan Stanley
(4.59)
# 242
Out of 5,113 analysts
233
Total ratings
65%
Success rate
17.3%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $197 → $200 | $224.44 | -10.89% | 27 | Jan 22, 2026 | |
| RCUS Arcus Biosciences | Downgrades: Equal-Weight | $23 → $20 | $22.99 | -13.01% | 9 | Jan 8, 2026 | |
| NRIX Nurix Therapeutics | Upgrades: Overweight | $15 → $36 | $19.41 | +85.47% | 7 | Jan 8, 2026 | |
| ALMS Alumis | Maintains: Overweight | $22 → $33 | $26.00 | +26.92% | 3 | Jan 7, 2026 | |
| BHVN Biohaven | Maintains: Overweight | $26 → $21 | $12.67 | +65.75% | 5 | Jan 6, 2026 | |
| PFE Pfizer | Maintains: Equal-Weight | $28 → $27 | $26.50 | +1.89% | 21 | Dec 17, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $37 | $55.56 | -33.41% | 12 | Dec 12, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $100 → $102 | $107.92 | -5.49% | 20 | Dec 12, 2025 | |
| GPCR Structure Therapeutics | Maintains: Overweight | $120 → $125 | $89.51 | +39.65% | 2 | Dec 12, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $329 → $304 | $351.32 | -13.47% | 11 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $269 | $223.93 | +20.13% | 19 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $516 → $564 | $474.17 | +18.94% | 3 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,171 → $1,290 | $1,039.51 | +24.10% | 23 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $9 | $9.00 | - | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $54 | $40.74 | +32.55% | 13 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $133 → $131 | $119.34 | +9.77% | 5 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $328 → $435 | $476.78 | -8.76% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $13.62 | -19.24% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $54.26 | -41.02% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $14.83 | -25.83% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.14 | +273.83% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $174.12 | +150.40% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $354.75 | - | 2 | Oct 2, 2017 |
Johnson & Johnson
Jan 22, 2026
Maintains: Equal-Weight
Price Target: $197 → $200
Current: $224.44
Upside: -10.89%
Arcus Biosciences
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $20
Current: $22.99
Upside: -13.01%
Nurix Therapeutics
Jan 8, 2026
Upgrades: Overweight
Price Target: $15 → $36
Current: $19.41
Upside: +85.47%
Alumis
Jan 7, 2026
Maintains: Overweight
Price Target: $22 → $33
Current: $26.00
Upside: +26.92%
Biohaven
Jan 6, 2026
Maintains: Overweight
Price Target: $26 → $21
Current: $12.67
Upside: +65.75%
Pfizer
Dec 17, 2025
Maintains: Equal-Weight
Price Target: $28 → $27
Current: $26.50
Upside: +1.89%
Bristol-Myers Squibb Company
Dec 12, 2025
Maintains: Underweight
Price Target: $36 → $37
Current: $55.56
Upside: -33.41%
Merck & Co.
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $100 → $102
Current: $107.92
Upside: -5.49%
Structure Therapeutics
Dec 12, 2025
Maintains: Overweight
Price Target: $120 → $125
Current: $89.51
Upside: +39.65%
Amgen
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $329 → $304
Current: $351.32
Upside: -13.47%
Dec 12, 2025
Maintains: Overweight
Price Target: $261 → $269
Current: $223.93
Upside: +20.13%
Dec 5, 2025
Maintains: Overweight
Price Target: $516 → $564
Current: $474.17
Upside: +18.94%
Nov 24, 2025
Maintains: Overweight
Price Target: $1,171 → $1,290
Current: $1,039.51
Upside: +24.10%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $10 → $9
Current: $9.00
Upside: -
Oct 10, 2025
Maintains: Overweight
Price Target: $55 → $54
Current: $40.74
Upside: +32.55%
Oct 10, 2025
Maintains: Overweight
Price Target: $133 → $131
Current: $119.34
Upside: +9.77%
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $328 → $435
Current: $476.78
Upside: -8.76%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $13.62
Upside: -19.24%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $54.26
Upside: -41.02%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $14.83
Upside: -25.83%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.14
Upside: +273.83%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $174.12
Upside: +150.40%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $354.75
Upside: -